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Lynx1 regulates synaptic plasticity in the brain by regulating nicotinic acetylcholine receptors (nAChRs).
It is not known to which extent Lynx1 can bind to endogenous nAChR subunits in the brain or how this
interaction is affected by Alzheimer’s disease pathology. We apply afﬁnity puriﬁcation to demonstrate
that a water-soluble variant of human Lynx1 (Ws-Lynx1) isolates a3, a4, a5, a6, a7, b2, and b4 nAChR
subunits from human and rat cortical extracts, and rat midbrain and olfactory bulb extracts, suggesting
that Lynx1 forms complexes with multiple nAChR subtypes in the human and rodent brain. Incubation
with Ws-Lynx1 decreases nicotine-mediated extracellular signaleregulated kinase phosphorylation in
PC12 cells and striatal neurons, indicating that binding of Ws-Lynx1 is sufﬁcient to inhibit signaling
downstream of nAChRs. The effect of nicotine in PC12 cells is independent of a7 or a4b2 nAChRs, sug-
gesting that Lynx1 can affect the function of native non-a7, non-a4b2 nAChR subtypes. We further show
that Lynx1 and oligomeric b-amyloid1e42 compete for binding to several nAChR subunits, that Ws-Lynx1
prevents b-amyloid1e42einduced cytotoxicity in cortical neurons, and that cortical Lynx1 levels are
decreased in a transgenic mouse model with concomitant b-amyloid and tau pathology. Our data suggest
that Lynx1 binds to multiple nAChR subtypes in the brain and that this interaction might have functional
and pathophysiological implications in relation to Alzheimer’s disease.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ly-6/neurotoxin (Lynx) protein Lynx1 is a glycophosphatidy-
linositol-anchored membrane protein that is structurally similar to
the snake toxina-bungarotoxin (Miwaet al.,1999), a potent inhibitor
of muscle-type and a7 nicotinic acetylcholine receptors (nAChRs)
(Tsetlin et al., 2009). In linewith this, Lynx1 has been shown to form
complexes with and negatively modulate the response of a7 and
a4b2 nAChRs in heterologous expression systems (Fu et al., 2012;
Ibañez-Tallon et al., 2002). Lynx1 is expressed in both gluta-
matergic and g-aminobutyric acid-ergic (GABAergic) neurons in theg Design & Pharmacology,
-2100 Copenhagen, Denmark.
.S. Thomsen).
r Inc. This is an open access article ubrain (Demars andMorishita, 2014). Lynx protein is enriched on the
cell membrane and in synapses (Thomsen et al., 2014), and Lynx1,
acting through nAChRs, is critical for the loss of synaptic plasticity in
the visual cortex that occurs during postnatal development
(Morishita et al., 2010). These results suggest that Lynx1 can
modulate nAChR function in the brainwith important consequences
for cholinergic-dependent synaptic plasticity [reviewed in (Miwa
et al., 2011, 2012; Thomsen and Mikkelsen, 2012)].
Alzheimer’s disease (AD) pathology is characterized by plaques
and neuroﬁbrillary tangles containing aggregated b-amyloid (Ab)
and hyperphosphorylated tau protein, respectively (Querfurth and
LaFerla, 2010). Soluble Ab species, particularly oligomeric Ab1e42,
are considered to be the most toxic form of Ab and are associated
with cognitive deﬁcits in AD (Lue et al., 1999; Walsh and Selkoe,
2007). Interestingly, soluble Ab1e42 interacts with and regulates
the function of several nAChR subtypes (Dougherty et al., 2003;nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2004). Although it remains to be established exactly how Ab1e42
and nAChRs interact and whether Ab1e42 produces positive or
negative modulation of nAChR function [reviewed in (Buckingham
et al., 2009; Parri and Dineley, 2010)], it has been convincingly
demonstrated that nAChR activation blocks Ab-mediated neuro-
toxicity in vitro (Kihara et al., 1997, 2001; Takada-Takatori et al.,
2006). Furthermore, the a7 nAChR has been shown to facilitate
intracellular accumulation of Ab1e42 in vitro (Nagele et al., 2002),
and reducing the interaction between Ab1e42 and the a7 nAChR
increases clearance of Ab1e42 in mice after intracerebroventricular
infusion of Ab1e42 (Wang et al., 2010). Moreover, crossing a7 nAChR
knockout mice (KO) with mice overexpressing amyloid precursor
protein (APP) leads to increased Ab production and affects memory
deﬁcits as well as neuropathology in APP-a7 KO mice
(Dziewczapolski et al., 2009; Hernandez et al., 2010). In addition,
binding of the a4b2 nAChR radioligand 18F-2FA-85380 was
decreased in several brain regions of AD patients, and this decrease
correlated with Ab load and cognitive performance in the medial
prefrontal cortex (Okada et al., 2013).
Combined with the observation that cholinergic neurons
degenerate and nAChR levels are decreased in AD (Auld et al., 2002;
Marutle et al., 2013; Okada et al., 2013), the aforementioned results
suggest that the interaction between nAChRs and Ab1e42 affects
cognitive function and may be involved in the pathophysiology of
AD.
Here, we investigate the ability of a previously characterized
recombinant soluble variant of human Lynx1 (Ws-Lynx1)
(Lyukmanova et al., 2011, 2013), to bind and regulate native nAChRs
in human cortical extracts and PC12 cells, respectively. We further
examine whether Ws-Lynx1 modulates the interaction between
oligomeric Ab1e42 and nAChRs.
2. Materials and methods
2.1. Human tissue and animals
Human temporal neocortical tissue was obtained from an
anterior temporal resection performed in a patient (female, age 44)
with medically intractable temporal lobe epilepsy with hippo-
campal onset. Written informed consent was obtained before sur-
gery. The study was approved by the Ethical Committee in the
Capital Region of Denmark (H-2-2011-104) and performed in
accordance with the Declaration of Helsinki. The tissue was
immediately frozen on dry ice and stored at 80 C until use. The
neuropathological examinations of the neocortex revealed no
abnormalities.
Four adultmale Sprague-Dawley rats (210e223 g)were obtained
from Charles River Laboratories (Sulzfeld, Germany) and housed 2
per cage. Animals were kept on a 12:12-hour light:dark cycle pro-
vided with standard rodent diet and water ad libitum. The animals
were acclimatized for a minimum of 7 days after arrival before ex-
periments began. They were decapitated, and the frontal cortex,
olfactory bulbs, and the lower part of the midbrain containing the
ventral tegmentum and substantia nigra were dissected. Samples
were pooled for further processing and stored at 80 C.
Triple transgenic mice (3Tg-AD) mice, expressing mutant
human transgenes (APP 695 with the Swedish double mutation
K670N/M671L [hAPPSwe] and tau P301L) and the presenilin-1
mutant M146 V knockin construct (Oddo et al., 2003) were
decapitated at 6 months (n ¼ 8) or 19e21 months (n ¼ 8) of age,
with age-matched wild-type (WT) mice (Sv129/B6; n ¼ 7e8) as
controls. The frontal cortex was dissected and immediately frozen
on dry ice and stored at 80 C until use. Data from these extracts
have also been used in another article (Jensen et al., 2015).2.2. Afﬁnity puriﬁcation
Two proteins were used as bait for afﬁnity puriﬁcation: A
recombinant water-soluble variant of human Lynx1 containing
amino acids 1e73 (ws-Lynx1), expressed in Escherichia coli and
puriﬁed as previously described (Shulepko et al., 2011) was dis-
solved to 2 mg/mL in phosphate-buffered saline (PBS), pH 7.4, at
4 C for 72 hours. Preparation of oligomeric Ab1e42 and the reverse
peptide Ab42e1 was performed according to the study by Stine et al.
(2003). Brieﬂy, Ab1e42 or Ab42e1 (SigmaeAldrich) were dissolved to
1mM in ice-cold 1,1,1,3,3,3-hexaﬂuoro-2-propanol, evaporated, and
stored at 20 C. Before use, 100 mg aliquots were resuspended in
4.4 mL dimethyl sulfoxide (DMSO), vortexed, and diluted to 200 mM
in PBS followed by incubation for 24 hours at 4 C to form oligo-
meric amyloid. Ws-Lynx1 or oligomeric Ab1e42 were coupled to
PureProteome NHS Flexibind magnetic beads (Millipore, Billerica,
MA, USA) in a ratio of 1:2 (v/v) using the manufacturer’s in-
structions. Successful coupling was conﬁrmed by subsequent pro-
tein determination showing more than 50% decrease in the protein
content of the solution. Another batch of beads was processed in
parallel but treated with PBS devoid of bait protein as a negative
control. The beads were incubated in 0.1% bovine serum albumin in
PBS, pH 7.4 1 hour at 4 C before use.
The tissue was lysed in 1 mL lysis buffer (50 mM Tris, 50 mM
NaCl, 5 mM EDTA, 5 mM ethylene glycol-bis(b-aminoethyl ether)-
N,N,N0,N0-tetraacetic acid (EGTA), 10 mL/mL protease inhibitor
cocktail [SigmaeAldrich, Brøndby, Denmark], pH 7.5) using a
PT1200C polytron blender (Kinematica, Luzern, Switzerland) for
20 seconds. The lysatewas centrifuged 30minutes at 160,000 g at
20 Ce22 C using an air-driven ultracentrifuge (Airfuge, Copen-
hagen, Denmark), and the supernatant discarded. The pellet was
resuspended in 1 mL lysis buffer containing 2% Triton X-100 by
blending for 20 seconds and incubated 2 hours at 4 C on a rotor
(15 rpm). Thereafter, the sample was centrifuged as previously
mentioned, and the resulting supernatant was used for afﬁnity
puriﬁcation. Total protein content was determined using the Pierce
660 nm Protein Assay (Thermo Scientiﬁc, Rockford, IL, USA), and
500e1000 mg of protein was incubated with 50 mL magnetic beads
in a total volume of 1500 mL lysis buffer for 18e22 hours at 4 C on a
vertical rotor (15 rpm). Subsequently, the beads were washed twice
in 1-M NaCl, 8 mM Na2HPO4, 2 mM NaH2PO4, 0.5% Triton X-100, pH
7.5 and 3 times in 0.1-M NaCl, 8 mMNa2HPO4, 2 mMNaH2PO4, 0.5%
Triton X-100, pH 7.5 and immediately processed for Western
blotting.
For experiments including preincubation with Ab1e42 or Ab42e1,
tissue extracts were homogenized and split into 2 aliquots. 1.5 mL of
200 mM oligomeric Ab1e42 or Ab42e1 or vehicle (4% DMSO in PBS)
was added to the respective aliquots followed by incubation for
60 minutes on ice before addition of beads. The experiment with
Ws-Lynx1 preincubation was performed by addition of 100 mL 50
mM Ws-Lynx1 or vehicle in a total volume of 500 mL.
2.3. Western blotting
Total protein content was measured using a DC Protein Assay
Kit (Biorad, Hercules, CA, USA). Equal amounts of lysates were then
diluted in loading buffer (120 mM Tris, 20% [v/v] glycerol, 10% [v/v]
mercaptoethanol, 4% [w/v] sodium dodecyl sulphate, and 0.05%
[w/v] bromophenol blue, pH 6.8), incubated for 5 minutes at 95 C
and submitted to gel electrophoresis using AnykD gels (Biorad),
and blotted onto polyvinylidene ﬂuoride membranes (BioRad).
Membranes were washed in tris-buffered saline with 0.1% Tween
20 (TBS-T) and blocked in TBS containing 5% (w/v) dry milk
powder, which was also used for antibody incubations. Incubation
with primary antisera directed against Lynx1 (1:1000, #sc-23060,
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kindly provided by Dr Cecilia Gotti); a3, a4, a5, a6, and 5-HT3
(1:100 #sc-1771, sc-5591, sc-28795, sc-27292, and sc-28958 Santa
Cruz Biotechnology); a7, b4 (1:1000 #ab23832 and 1:100
#ab156213 Abcam, Cambridge, UK); Actin (1:10,000, #A5060,
SigmaeAldrich); pERK1/2 (1:4000 #9101 Cell Signaling, Leiden,
The Netherlands); or ERK1 (1:4,000, #610031, BD Transduction
Laboratories, Franklin Lakes, NJ, USA) was performed overnight at
4 C on paraﬁlm in a humidiﬁed container, followed by 3 
10 minute washes in TBS-T and 1 hour incubation at 20 Ce22 C
with horseradish peroxidase-conjugated secondary antibody
(1:2000, Dako, Glostrup, Denmark). After thorough washing in
TBS-T, enhanced chemiluminescence Western blotting detection
reagents (Western Lightning ECL Pro, Perkin Elmer, Waltham, MA,
USA) were used for signal detection, and protein bands were
visualized using a Chemidoc XR digital image analyser (Biorad). In
the experiments with minced slices, total protein content as
measured by Stain-Free technology (Biorad) was used to normalize
band intensity. Mean optical densities of bands were measured
and their corresponding background measurement subtracted.
Molecular weights were estimated by comparing with dyed pro-
tein markers (PageRuler Prestained Protein Ladder, Thermo
Scientiﬁc).
2.4. PC12 cell culturing and ERK phosphorylation assay
PC12 cells weremaintained in 75 cm2 ﬂasks coatedwith 5 mg/mL
poly-L-lysine (SigmaeAldrich, Brøndby, Denmark), in Dulbecco’s
modiﬁed Eagle medium (DMEM, Gibco Life Technologies, NY, USA)
supplemented with 10% heat inactivated horse serum, 5% fetal
bovine serum, 25-U/mL penicillin, 25 mg/mL streptomycin, 1 mM
sodium pyruvate, and 2 mM glutamine at 37 C in a humidiﬁed
incubator with 5% CO2. Cells were subcultured every 3e4 days by
detachment with 0.25% trypsin in EDTA solution (Life Technologies,
NY, USA) and re-seeded at 15% conﬂuence.
For the extracellular signaleregulated kinase (ERK) phosphor-
ylation assay, cells were seeded in 24-well plates at 12  104 cells/
cm2, 24 hours before the experiment. On the day of the experiment,
cells were incubated for 10minutes withWs-Lynx1, mecamylamine
(SigmaeAldrich), dihydro-b-erythroidine (DhbE, Tocris Bioscience,
Bristol, UK), methyllycaconitine (MLA, Santa Cruz Biotechnology),
or the a-conotoxins AuIB, PIA, or MII (Tocris) diluted in
DMEM, followed by 5 minutes stimulation with 25 mM nicotine
(SigmaeAldrich). Thereafter, cells were lysed in 100 mL ice-cold lysis
buffer/well (100 mMNaCl, 25 mM EDTA,10mM Tris, 4 mMNa3VO4,
1 mM NaF, 1 % [v/v] Triton X-100, 1 % [v/v] NP-40, 1 mL/mL protease
inhibitor cocktail [SigmaeAldrich], pH 7.4). To ensure complete
lysis, lysates were then placed at 80 C for 15 minutes, thawed,
and sonicated for 5 seconds on ice. Lysates were stored at 80 C
until use.
2.5. ERK phosphorylation in minced slices
Frontal cortex and striatum were dissected from 4 male Wistar
rats (Charles River, Germany) weighing 200e300 g, chopped with
150 mm intervals 3 times with a 60-degree rotation in between
using a tissue chopper (Brinkman Instruments, Westbury, NY, USA).
The resulting minced slices were resuspended in 37 C Krebs buffer
(KB: 118 mM NaCl, 2.4 mM KCl, 2.4 mM CaCl2, 1.2 mM MgSO4, 1.2
KH2PO4, 25 mM NaHCO3, 10 mM D-glucose, oxygenated with 95%
O2/5% CO2 for 1 hour, pH 7.4) and triturated 10 times to further
dissociate the tissue. Slices were washed in KB and incubated at
37 C for 30minutes while shaking. About 90 mL of the resuspended
minced slices was added to tubes containing 10 mL of vehicle (KB),
nicotine, Ws-Lynx1, and nicotine or KCl and incubated for another5 minutes at 37 C with vigorous shaking. Then, 100 mL of
lysis buffer (radioimmunoprecipitation assay buffer) with 8%
b-mercaptoethanol and 4% sodium dodecyl sulphate, 1 mL/mL pro-
tease inhibitor cocktail, 4 mM Na3VO4, 1 mM NaF was added, and
the samples were quickly frozen to 80 C to lyse the cells further,
thawed and submitted to gel electrophoresis and Western blotting.
To ensure uniformity, 1 set of samples were processed in parallel.
Therefore, repeated measures analysis of variance (ANOVA) was
used for statistical calculations.2.6. Messenger RNA (mRNA) extraction and quantitative PCR
(qPCR)
Total RNA was isolated using an RNeasy Mini Kit (Qiagen,
Copenhagen, Denmark) according to the manufacturer’s
instructions. RNA samples were dissolved in RNase-free water,
and RNA content was quantiﬁed using a Nanodrop ND-1000
Spectrophotometer (Nanodrop Technologies, Wilmington, DE,
USA). Samples were diluted with RNase-free water to equal RNA
concentrations and reverse transcribed into single-stranded
complementary DNA (cDNA) with the ImProm-II Reverse Tran-
scription System (Promega, Madison, WI, USA) according to the
manufacturer’s directions using 0.5 mg/reaction oligo(dT)15
primers, 6 mM MgCl2, and 20 units of RNase inhibitor. Real-time
qPCR reactions were performed in a total volume of 20 mL, con-
taining 1 mL sample cDNA, 1  Brilliant II SYBR Green QPCR
Master Mix (Stratagene, La Jolla, CA, USA), and 15 pmol each of
the forward and reverse primers (DNA Technology, Aarhus,
Denmark). Primers used were for the following transcripts:
GAPDH, a2, a3, a4, a5, a6, a7, a9, b2, b3, and b4. Primer sequences
can be found in Table S1. PCR was performed on a Light Cycler 480
Real-Time PCR System (Roche, Indianapolis, IN, USA) with a
10-minute preincubation at 94 C followed by 40 cycles of
30 seconds at 94 C, 45 seconds at 60 C, and 90 seconds at 72 C.
Primer pairs were validated by using serially diluted cDNA to
establish a standard curve and by conﬁrming the existence of a
single product on a gel at the correct molecular weight. Quanti-
ﬁcation of mRNA expression was performed according to the
comparative CT method as described by Schmittgen and Livak
(2008). For each sample, the amount of target mRNA was
normalized to the amount of GAPDH.2.7. Cortical neurons and cytotoxicity assay
Cultures of cortical neurons were prepared from E15 mouse
fetuses, according to a previously published protocol (Walls et al.,
2014). Neurons were seeded at 250,000 cells per well in 96-well
plates. At days in vitro 6, the medium was exchanged for
DMEM  0.01e10 mM Ws-Lynx1. After 2 hours, 20 mM oligomeric
Ab1e42 or vehicle (4% DMSO in DMEM) was added, and the cells
were incubated for an additional 24 hours. The release of cyto-
plasmic lactate dehydrogenase (LDH) into the culture medium was
analyzed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay
(Promega, San Luis Obispo, CA, USA), according to the manufac-
turer’s instructions. Brieﬂy, the culture medium was removed and
spun to remove cellular residue. Then, 50 mL of a 1:10 dilution of
each sample was incubated with 50 mL of a substrate mix for
30 minutes in the dark after which the reaction was stopped by
addition of 50 mL of 1-M acetic acid. Finally, the color intensity was
measured at 490 nm using a plate reader. A parallel group of wells
were lysed by addition of Triton X-100 (ﬁnal concentration 2%) to
get the total LDH content of the cells. The results are presented as
the ratio of LDH released compared with the total amount of LDH
from the medium and the cells.
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Data sets that passed Bartlett’s test for standard deviations were
analyzed using 2-way ANOVA followed by Tukey’s multiple compari-
sons test, 1-way or repeated measures ANOVA followed by Dunnett’s
multiple comparisons test, ratio paired or unpaired t-tests. Otherwise,
the KruskaleWallis test followed by Dunn’smultiple comparisons test
was used. The statistical calculations were performed using GraphPad
Prismversion6 forWindows (GraphPadSoftware, SanDiego, CA,USA).
All data are presented as mean  standard error of the mean, and a
p-value of less than 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Ws-Lynx1 binds to multiple nAChR subtypes in human and rat
brain extracts
To determine whether Ws-Lynx1 could bind native nAChR
subunits, we performed afﬁnity puriﬁcation using bead-coupled
Ws-Lynx1 as bait. Ws-Lynx1 was able to isolate the a3, a4, a5, a6,
a7, b2, and b4 nAChR subunits in extracts from human temporal
cortex (Fig. 1A) as well as in extracts from rat neocortex, midbrain,
and olfactory bulbs (Fig. 1B). Ws-Lynx1 did not isolate subunits of
the closely related 5-HT3 receptor in any of the extracts. None of the
subunits were detected when the afﬁnity puriﬁcation was per-
formed using noncoupled beads, conﬁrming that isolation of nAChR
subunits was attributable to a speciﬁc interaction with Ws-Lynx1.
The detection of the a7, b2, and b4 subunits was validated by
showing that these subunits were not detected after Ws-Lynx1
afﬁnity puriﬁcation on cortical extracts from their respective
knockout mice (Fig. S1).
3.2. Ws-Lynx1 affects the function of non-a7, non-a4b2 nAChRs in
rat PC12 cells
About 25 mM of nicotine induced phosphorylation of the MAP
kinase ERK in PC12 cells. Preincubation with Ws-Lynx1 atFig. 1. Ws-Lynx1 binds multiple nAChR subunits in the human and rat brain. Afﬁnity puriﬁca
human Lynx1 (Lynx1) or noncoupled beads (Ctrl) on homogenates (Hom) from (A) human tem
tegmentum and substantia nigra (VTA/SN) and olfactory bulb (OLF). Samples were submitte
and the 5-HT3 receptor. Abbreviation: nAChR, nicotinic acetylcholine receptor.0.1e10 mM dose-dependently reduced the nicotine-mediated
increase in ERK phosphorylation, reaching signiﬁcance at 10 mM
(53% reduction, p < 0.001, Fig. 2A and B).
The effect of nicotinewas also abolished by preincubationwith 1
and 10 mM of the nAChR pore blocker mecamylamine (p < 0.01 and
p < 0.001, respectively) and by the a-conotoxin AuIB, which
selectively inhibits a3b4-containing nAChRs (Luo et al., 1998), but
neither by 1 or 10 mM DhbE nor by 10 or 100 nM MLA, which are
selective for a4b2 and a7 nAChRs, respectively and neither by the
a-conotoxins PIA nor MII that selectively inhibit a6-or a3b2-
containing nAChRs, respectively (Cartier et al., 1996; Dowell et al.,
2003) (Fig. 2C). Real-time qPCR on extracts from PC12 cells
revealed the presence of the nAChR subunits a2-7, a9, and b2-4,
although the degree of expression varied 43-fold from a3 with the
highest expression to a4 with the lowest expression (Fig. 2D).
3.3. Ws-Lynx1 reduces nicotine-induced ERK phosphorylation in
striatal slices
25 mM nicotine signiﬁcantly induced ERK phosphorylation in
acutely dissociated minced slices from rat frontal cortex and stria-
tum (22%, p< 0.05 and 13%, p< 0.05 increase compared to vehicle).
Ws-Lynx1 at 0.1e10 mM did not affect the nicotine-mediated
increase in ERK phosphorylation in frontal cortical slices, but
dose-dependently reduced it in striatal slices, reaching signiﬁcance
at 10 mM (98% reduction, p < 0.01, Fig. 3).
3.4. Ab1e42 and Ws-Lynx1 compete for binding to nAChRs in rat
cortical extracts
Preincubation of rat frontal cortical extracts with 200 nM oligo-
meric Ab1e42 signiﬁcantly reduced the amount of a3 (23%, p< 0.05),
a4 (20%, p < 0.05), a5 (25%, p < 0.05), and a7 (15%, p < 0.05) nAChR
subunits that were isolated by afﬁnity puriﬁcation with Ws-Lynx1
(Fig. 4A and B), compared with parallel samples afﬁnity puriﬁed in
the absence of Ab1e42. Ab1e42 did not signiﬁcantly alter the puriﬁ-
cation of a6, b2, or b4 nAChR subunits.tion was performed using magnetic beads covalently coupled with recombinant soluble
poral cortex and (B) rat cortex (CTX), lower part of the midbrain containing the ventral
d to gel electrophoresis and Western blotting followed by detection of nAChR subunits
Fig. 2. Ws-Lynx1 reduces nicotine-mediated nAChR signaling in PC12 cells. (A) Nicotine elicits an increase in extracellular signaleregulated kinase (ERK) phosphorylation in PC12
cells, and this response is reduced by preincubation with 10 mM recombinant soluble human Lynx1 (Ws-Lynx1). Values are presented as the ratio between phosphorylated (pERK)
and total ERK (totERK) protein and normalized to the 25 mM nicotine group (n ¼ 4e6 wells). (B) Representative images of Western blots summarized in (A). (C) Preincubation with 1
and 10 mM of mecamylamine (n ¼ 4), and 5- and 15-mM a-conotoxin AuIB (n ¼ 4), but not with dihydro-b-erythroidine (DhbE, n ¼ 7e8), 10e100 nM of methyllycaconitine (MLA, n ¼
20), or 0.03e3 mM of the a-conotoxins PIA or MII (n ¼ 4), inhibited ERK phosphorylation in response to 25 mM nicotine. (D) Messenger RNA levels of nAChR subunits in PC12 cells
normalized to the levels of GAPDH (n ¼ 3e6). **p < 0.01 and ***p < 0.001 indicate statistical difference from the 25 mM nicotine group in a 1-way analysis of variance with Dunnett’s
multiple comparison test. Abbreviation: nAChR, nicotinic acetylcholine receptor.
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not affect the amount of any of the measured nAChR subunits pu-
riﬁed using Ws-Lynx1 (Fig. 4C).
We found that bead-coupled oligomeric Ab1e42 was able to
isolate all the nAChR subunits assayed (Fig. 4D). Further, pre-
incubation with 10 mMWs-Lynx1 signiﬁcantly reduced the amount
of a4 (23%, p < 0.05), a7 (30%, p < 0.05), and b2 (32%, p < 0.05)
nAChR subunits that were isolated by afﬁnity puriﬁcation with
oligomeric Ab1e42 (Fig. 4D and E). Ws-Lynx1 did not signiﬁcantly
alter the puriﬁcation of a3, a5, a6, or b4 nAChR subunits.
Afﬁnity puriﬁcationwithWs-Lynx1 frompure solutions of 200 nM
oligomeric Ab1e42 did not yield detectable isolation of Ab1e42 (Fig. S2).
3.5. Ws-Lynx1 prevents Ab1e42-induced cytotoxicity in vitro
Incubation of mouse cortical neurons with 20 mM oligomeric
Ab1e42 for 24 hours signiﬁcantly increased the amount of LDH
released into themedia fromtheneurons (Fig. 5). This effect ofAb1e42
was signiﬁcantly reduced by preincubating the neurons with 0.1 and
10 mMWs-Lynx1 for 2 hours (p < 0.05 and p < 0.01, respectively).
3.6. Lynx1 levels are reduced in transgenic mice with amyloid and
tau pathology
Lynx1 levels were measured in the frontal cortex of 6 or 19 to
21-month-old 3Tg-AD mice compared with age-matched WTmice (Fig. 6). A 2-way ANOVA revealed a signiﬁcant main effect of
both genotype and age (both p < 0.05), indicating that 3Tg-AD
mice have signiﬁcantly lower Lynx1 levels compared withWTmice
and that 19 to 21-month-old mice had signiﬁcantly higher Lynx1
levels compared with 6-month-old mice. Subsequent multiple
comparisons revealed a signiﬁcantly lower level of Lynx1 in 19 to
21-month-old 3Tg-AD mice compared with age-matched WT
mice (p < 0.01).
4. Discussion
Our main ﬁndings are that Ws-Lynx1 forms complexes with
multiple native nAChR subunits in human brain extracts and that
Ab1e42 and Ws-Lynx1 compete for binding to nAChRs.
Lynx1 protein has attracted attention because it was shown that
murine Lynx1 co-immunoprecipitates with and inhibits the func-
tion of a7 and a4b2 nAChRs in heterologous expression systems
(Ibañez-Tallon et al., 2002). However, it has remained unclear
whether this was also true for native nAChRs and whether Lynx1
interactions were limited to a7 and a4b2 nAChRs. Here, we apply
afﬁnity puriﬁcationwithWs-Lynx1 to show that it forms complexes
with nAChRs containing a3, a4, a5, a6, a7, b2, and b4 nAChR
subunits in extracts from human cortex as well as rat cortex,
midbrain, and olfactory bulb. This is in stark contrast to the related
Lynx protein, SLURP-1, which we have recently shown to selectively
form complexes with the a7 subunit in human cortical extracts
Fig. 3. Ws-Lynx1 reduces nicotine-mediated nAChR signaling in striatal slices. Nicotine
of 25 mM elicits an increase in ERK phosphorylation in frontal cortical and striatal slices.
The response in striatal, but not frontal cortical slices, is reduced by preincubation with
10 mM recombinant soluble human Lynx1 (Ws-Lynx1). Values are presented as the
ratio between phosphorylated (pERK) and total protein content and normalized to the
degree of induction by 16 mM KCl (set to 100) and vehicle (set to 0), n ¼ 8. *p < 0.05
and **p < 0.01 indicate statistical difference from the 25 mM nicotine group in a
repeated analysis of variance measures with Dunnett’s multiple comparison
test. Abbreviations: ERK, extracellular signaleregulated kinase; nAChR, nicotinic
acetylcholine receptor.
Fig. 4. Oligomeric b-amyloid1e42 (Ab1e42) and Ws-Lynx1 compete for binding to nAChRs in t
in rat cortical extracts subjected to Ws-Lynx1 afﬁnity puriﬁcation in the presence of 200 nM
measuring the optical density (OD) for detection of the individual nAChR subunits, n ¼ 5 an
the reverse peptide Ab42e1 or vehicle (n ¼ 3). (D) Representative images of detection of nA
riﬁcation in the presence of 10 mMWs-Lynx1 or vehicle (Ctrl). (E) Quantiﬁcation of the data re
animals. Values are normalized to their individual vehicle. *p < 0.05 indicates statistical diffe
respectively, in a ratio paired t-test. Abbreviation: nAChR, nicotinic acetylcholine receptor.
M.S. Thomsen et al. / Neurobiology of Aging 46 (2016) 13e2118(Lyukmanova et al., 2016) and opens the possibility that Lynx1 can
modulate a wide range of nAChR-dependent signaling in the
human brain.
We have previously shown that a7b2 nAChRs remain intact
during the afﬁnity puriﬁcation assay used here (Thomsen et al.,
2015). We therefore believe it is unlikely that nAChRs are dissoci-
ated into individual subunits during the afﬁnity puriﬁcation. Our
data therefore do not necessarily imply that Ws-Lynx1 binds
directly to all these subunits. Rather, isolation of individual subunits
can occur so long as they are part of an nAChR subtype that is able to
bind to Ws-Lynx1.
To investigate the effect of Ws-Lynx1 on nAChR-mediated
signaling, we used nicotine-induced phosphorylation of ERK in
PC12 cells as a model system. We found that nicotine-induced
phosphorylation of ERK was not sensitive to MLA or DhbE, sug-
gesting that it was not due to activation of a7 or a4b2 nAChRs,
receptors which Lynx1 has previously been shown to interact with.
Rather, it was almost completely blocked by a-conotoxin AuIB,
suggesting that the effect of nicotine on ERK phosphorylation in
PC12 cells it is mainly caused by activation of a3b4 nAChRs. This is
in linewith a previous report (Nakayama et al., 2006). In accordance
with a role for Lynx1 as a regulator of multiple nAChR subtypes,
Ws-Lynx1 inhibited nicotine-mediated phosphorylation of ERK in
PC12 cells.
This suggests that Lynx1 also regulates non-a7, non-a4b2 nAChR
subtypes, and that inhibition by Lynx1 is sufﬁcient to inhibit
nAChR-mediated activation of the MAP kinase pathway, which is
important for LTP formation and memory function (Adams and
Sweatt, 2002). We further show that Ws-Lynx1 is able to inhibithe rat cortex. (A) Representative images of detection of nAChR subunits by Western blot
oligomeric Ab1e42 or vehicle (Ctrl). (B) Quantiﬁcation of the data represented in (A) by
imals. (C) Quantiﬁcation of Ws-Lynx1 afﬁnity puriﬁcation in the presence of 200 nM of
ChR subunits by Western blot in rat cortical extracts subjected to Ab1e42 afﬁnity pu-
presented in (D) by measuring OD for detection of the individual nAChR subunits, n ¼ 4
rence from afﬁnity puriﬁcation in the absence of b-amyloid or Ws-Lynx1 in (B) and (E),
Fig. 5. Ws-Lynx1 prevents b-amyloid1e42 (Ab1e42)-induced cytotoxicity in vitro. Mouse
cortical neurons were incubated with Ws-Lynx1 (0.01e10 mM) for 2 hours followed by
addition of 20 mM oligomeric Ab1e42 for an additional 24 hours. The release of lactate
dehydrogenase (LDH) to the media was used as a measure of cytotoxicity. Values are
presented as a fraction of the total LDH content in the cells, n ¼ 6e12. *p <0.05 and
**p < 0.01 indicate statistical difference from the 20 mM oligomeric Ab1e42 group in a
KruskaleWallis test with Dunn’s multiple comparison test.
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cortical, minced slices. Because the frontal cortex predominantly
expresses nAChRs of the a7 and a4b2 subtypes, whereas the
striatum has a more diverse pattern of expression (Gotti et al.,
2006), this suggests that Ws-Lynx1 may affect non-a7, non-a4b2
nAChR subtypes in the striatum. Notably, it has previously been
shown that Lynx1 modulates a7 and/or a4b2 nAChRs in the visual
cortex of mice in vivo (Morishita et al., 2010). The micromolar
concentration required for the inhibitory function of Ws-Lynx1 in
PC12 cells is in line with the concentration of Ws-Lynx1 required to
inhibit current ﬂow through a7 and a4b2 nAChRs expressed in
Xenopus oocytes (Lyukmanova et al., 2011). Our experiments
involve addition of soluble Ws-Lynx1 for relatively short time to
intact cells and therefore likely reﬂect an effect on membrane
surface nAChRs. In N2a cells, Lynx1 was recently reported to asso-
ciate with a4b2 nAChRs in the endoplasmic reticulum, where it
affected assembly of these receptors and reduced the sensitivity toFig. 6. Mice with b-amyloid and tau pathology have decreased Lynx1 levels in frontal cortex.
mice, which display concomitant b-amyloidosis and tau hyperphosphorylation. Mice were
Western blots. (B) Quantiﬁcation of Lynx1 levels normalized to Actin levels. # and * indicate
(n ¼ 7e8 animals). Abbreviations: AD, Alzheimer’s disease; OD, optical density; WT, wild-tacetylcholine (Nichols et al., 2014). Notably, these effects did not
seem to involve surface expression of Lynx1 as they were not
affected by cleaving surface glycophosphatidylinositol anchors
(Nichols et al., 2014). In another recent report, the Lynx proteins
Lynx2 and Ly6H were shown to regulate a7 nAChR surface activity
by retaining a7 nAChRs inside cells (Puddifoot et al., 2015). It thus
seems that Lynx proteins may affect nAChRs both by acting as
chaperones and as regulators of nAChR function at the cell surface.
It has previously been demonstrated that Ws-Lynx1 modulates
the activity of human a7 and a4b2 nAChRs, without inhibiting
binding of a-bungarotoxin to a7 nAChRs or epibatidine to a4b2
nAChRs expressed in GH4C1 and SH-EP1 cells, respectively,
(Lyukmanova et al., 2011). These data indicate that Ws-Lynx1 binds
outside of the orthosteric binding site on these neuronal nAChR
subtypes. Nevertheless, site-directed mutagenesis and computer
modeling suggest that the binding site for Ws-Lynx1 is close to the
orthosteric binding site on the a7 nAChR (Lyukmanova et al., 2013).
Ab1e42 is believed to bind the orthosteric binding site on the a7
nAChR (Maatuk and Samson, 2013). Therefore, we hypothesized that
Ab1e42 would be able to interfere with Lynx1-nAChR interactions
[reviewed in Thomsen et al. (2016)]. In line with this hypothesis, the
presence of oligomeric Ab1e42 signiﬁcantly decreased the amount of
a3, a4, a5, and a7 nAChR subunits isolated duringWs-Lynx1 afﬁnity
puriﬁcation. This suggests that Ws-Lynx1 and Ab1e42 may compete
for overlapping binding sites on these nAChR subunits. However,
because Ws-Lynx1 was not able to isolate Ab1e42, it does not seem
that these two proteins bind to each other. It is noteworthy that
Ab1e42 did not diminish the amount of isolated subunits of the b
type. Although we have previously demonstrated the integrity of
a7b2 nAChRs with the same sample preparation (Thomsen et al.,
2015), one possible explanation is that the pentameric organiza-
tion of nAChRs may be disrupted during sample preparation and
that Ws-Lynx1 binds to individual subunits rather than the entire
nAChR containing both a and b subunits. Bead-coupled oligomeric
Ab1e42 was able to isolate a3, a4, a5, a6, a7, b2, and b4 subunits from
rat cortical extracts. This extends previous ﬁndings demonstrating
that Ab1e42 interacts with a7, a4b2, a4a5b2 nAChRs (Dougherty
et al., 2003; Lamb et al., 2005; Pettit et al., 2001; Wang et al.,
2000; Wu et al., 2004). Further, Ws-Lynx1 inhibited the interac-
tion of oligomeric Ab1e42 with a4, a7, and b2 nAChRs. The difference
between the relative competition of soluble Ws-Lynx1 and oligo-
meric Ab1e42 likely reﬂects a difference in their relative afﬁnity
toward the respective nAChR subunits. It has been suggested that
physiological levels of Ab1e42 provide a trophic signal through
nAChRs, but that this is blocked or becomes toxic with excess levels
of Ab1e42, such as those found in AD (Parri and Dineley, 2010).
Because Ws-Lynx1 and Ab1e42 compete for binding to nAChRs,Lynx1 protein levels were analyzed in frontal cortical extracts from 3Tg-AD transgenic
sacriﬁced at 6 or 19e21 months of age. (A) Representative images of Lynx1 and Actin
p < 0.05 main effects of genotype and age, respectively, in a 2-way analysis of variance
ype.
M.S. Thomsen et al. / Neurobiology of Aging 46 (2016) 13e2120endogenous Lynx1 may be able to diminish the detrimental effects
of excess Ab1e42 seen in AD by reducing the sensitivity of nAChRs for
Ab1e42. In line with this, we show that Ws-Lynx1 prevents Ab1e42-
induced cytotoxicity in mouse cortical neurons.
In the frontal cortex of 3Tg-AD mice, which display both
increased Ab levels and tau hyperphosphorylation (Oddo et al.,
2003), we found decreased Lynx1 protein levels compared with
age-matched WT mice. This is in contrast to another Lynx protein,
prostate stem cell antigen, that we have recently found to be
upregulated in postmortem frontal cortex of patients with AD
(Jensen et al., 2015).
It is conceivable that a lower availability of Lynx1 protein pro-
motes Ab1e42-nAChR interactions in this animal model of AD. In this
regard, it is noteworthy that Lynx1 KO mice display nAChR-
dependent neuronal degeneration with age (Kobayashi et al.,
2014; Miwa et al., 2006), suggesting that Lynx1 has a neuro-
protective role by dampening excess activation of nAChRs.
In summary, we hypothesize that in AD a combination of excess
Ab1e42 and decreased Lynx1 levels may act in concert to confer
Ab1e42-mediated toxicity through nAChRs. Notably, a7 nAChRs
have been shown to facilitate intracellular accumulation of Ab1e42
(Nagele et al., 2002), and intracellular Ab has been shown to trigger
cognitive deﬁcits in 3Tg-AD mice (Billings et al., 2005). Dissoci-
ating Ab-nAChR interactions, such as with Lynx1, may therefore
ameliorate the cognitive deﬁcits seen in AD.
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